Main Newsletter
Mastery Series
Therapy Series
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  BG ControlType 2 DiabetesSGLT2Issue 731

AACE: Dapagliflozin Reduces Postprandial Glucose in Type 2 Diabetes

Dapagliflozin as an add-on therapy to glimepiride, pioglitazone, or sitagliptin significantly reduces postprandial plasma glucose in type 2 diabetes patients.... 


The US Food and Drug Administration approved dapagliflozin on January 8, 2014, for use in glycemic control, along with diet and exercise, in adults with type 2 diabetes.

Dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, lowers plasma glucose concentration by increasing renal glucose excretion, independent from insulin secretion.

The authors point out that control of fasting hyperglycemia alone may not be optimal for achieving long term glucose control, as indicated by HbA1c <7.0%, in patients with type 2 diabetes mellitus (T2DM). The current study evaluated postprandial glucose.

In three phase 3 randomized trials, type 2 diabetes patients received 10 mg/day dapagliflozin or placebo as an add-on therapy to glimepiride (n=596), pioglitazone (n=420) and sitagliptin with or without metformin (n=451).

The study showed that the addition of dapagliflozin significantly reduced postprandial plasma glucose compared with placebo: placebo-corrected mean changes from baseline at 24 weeks in 2-hour postprandial plasma glucose for dapagliflozin were -49.1 (-64.1, -34.1) mg/dL with glimepiride, -53.3 (-71.1, -35.6) mg/dL with pioglitazone, and -42.9 (-52.1, -33.8) mg/dL with sitagliptin.

According to the authors, "Observational studies suggest that postprandial glucose may be more predictive of cardiovascular morbidity and mortality and microvascular complications than fasting plasma glucose.

"Higher postprandial blood glucose concentrations may lead to increased glucose filtration, allowing for greater glucose excretion with SGLT2 inhibition and effective postprandial glucose lowering, thus potentially preventing vascular complications," the authors write.

Practice Pearls:
  • The addition of dapagliflozin significantly reduced postprandial plasma glucose compared with placebo
  • PPG may be more predictive of cardiovascular morbidity and mortality and microvascular complications than fasting plasma glucose.
  • The number of adverse events was similar for dapagliflozin and placebo.

The study was presented at the American Association of Clinical Endocrinologists annual meeting held from May 14th to 18th in Las Vegas, Nevada. 



Bookmark and Share | Print | Category | Home

This article originally posted 29 May, 2014 and appeared in  BG ControlType 2 DiabetesSGLT2Issue 731

Past five issues: Diabetes Clinical Mastery Series Issue 216 | Issue 756 | Diabetes Clinical Mastery Series Issue 215 | SGLT-2 Inhibitors Special Edition November 2014 | Issue 755 |

2014 Most Popular Articles:

Grapefruit Juice May Affect Insulin Resistance
Posted October 23, 2014
New SGLT2 Inhibitor Likely To Be Approved for Type 2 Diabetes
Posted November 14, 2014
FDA Accepts Filing of NDA for Empagliflozin/Metformin Fixed-dose Combination
Posted October 23, 2014
Dietary Magnesium Intake's Role in Decreasing Metabolic Syndrome
Posted October 31, 2014
What's Hiding in that Insulin Box?
Posted October 27, 2014
Handbook of Diabetes, 4th Ed., Excerpt #16: Diabetic Neuropathy
Posted November 02, 2014
New Approach Targets Type 2's Poorly Controlled With Metformin
Posted November 14, 2014
Very Low Carbohydrate, Low Saturated Fat Diet for Type 2 Diabetes Management
Posted November 07, 2014
Interview with NuSirt CEO Joe Cook, Jr: Improving Metformin Treatment, Part 1
Posted November 02, 2014
Exenatide a Noninsulin Addition for Patients Failing Basal Insulin
Posted October 23, 2014

Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
If the U.S. Affordable Care Act is reversed in the new congress, what impact will that have on your patients?
CME/CE of the Week
Vickie Driver, DPM, MS, FACFAS

Category: Wound Care
Credits: 1.0

Search Articles On Diabetes In Control